RUNX1T1: A novel predictor of liver metastasis in primary pancreatic endocrine neoplasms

Pancreas

Volumn 40, Issue 4, 2011, Pages 627-633

  Nasir, Aejaz ^a,b   Helm, James ^c   Turner, Leslie ^c   Chen, Dung Tsa ^a   Strosberg, Jonathan ^c   Hafez, Naiel ^c   Henderson Jackson, Evita B ^c   Hodul, Pamela ^a   Bui, Marilyn M ^a   Nasir, Nelly A ^d   Hakam, Ardeshir ^a   Malafa, Mokenge P ^d   Yeatman, Timothy J ^d   Coppola, Domenico ^a   Kvols, Larry K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

endocrine neoplasm; immunohistochemistry; pancreas; predictor of metastasis; progression marker; RUNX1T1

Indexed keywords

TRANSCRIPTION FACTOR RUNX1;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; TISSUE MICROARRAY; TUMOR NECROSIS; TUMOR VOLUME;

ADULT; AGED; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEOMICS; PROTO-ONCOGENE PROTEINS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS;

EID: 79955067032     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182152bda     Document Type: Article

References (32)

1. Kulke M. Advances in the treatment of neuroendocrine tumors. Curr Treat Options Oncol. 2005; 6:397-409. (Pubitemid 41684220)
2. Oberg K, Eriksson B. Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol. 1989; 28:425-431. (Pubitemid 19166905)
3. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997; 79:813-829. (Pubitemid 27076348)
4. DeLellis R, Lloyd R, Heitz P, et al. Pathology and Genetics of Tumors of Endocrine Organs. Lyon, France: IARC Press; 2004.
5. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002; 20:2633-2642. (Pubitemid 34575635)
6. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449:395-401. (Pubitemid 44451313)
7. Phan GQ, Yeo CJ, Hruban RH, et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg. 1998; 2:472-482.
8. Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007; 25: 5609-5615.
9. Alexiev BA, Drachenberg CB, Papadimitriou JC. Endocrine tumors of the gastrointestinal tract and pancreas: grading, tumor size and proliferation index do not predict malignant behavior. Diagn Pathol. 2007; 2:28.
10. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas. 2009; 38:255-258.
11. Maitra A, Hansel DE, Argani P, et al. Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res. 2003; 9:5988-5995. (Pubitemid 38018085)
12. Bloomston M, Durkin A, Yang I, et al. Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies. Ann Surg Oncol. 2004; 11:413-419. (Pubitemid 40486752)
13. Capurso G, Lattimore S, Crnogorac-Jurcevic T, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer. 2006; 13:541-558. (Pubitemid 43886676)
14. Dilley WG, Kalyanaraman S, Verma S, et al. Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome. Mol Cancer. 2005; 4:9.
15. Couvelard A, Hu J, Steers G, et al. Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. Gastroenterology. 2006; 131:1597-1610. (Pubitemid 44780863)
16. Duerr EM, Mizukami Y, Ng A, et al. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer. 2008; 15:243-256. (Pubitemid 351449743)
17. Shida T, Furuya M, Kishimoto T, et al. The expression of NeuroD and mASH1 in the gastroenteropancreatic neuroendocrine tumors. Mod Pathol. 2008; 21:1363-1370.
18. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993; 85:200-206. (Pubitemid 23046895)
19. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314:268-274. (Pubitemid 44571966)
20. Pratap J, Lian JB, Javed A, et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev. 2006; 25:589-600. (Pubitemid 46071865)
21. Robinson HM, Broadfield ZJ, Cheung KL, et al. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia. 2003; 17:2249-2250. (Pubitemid 37428400)
22. Barnes GL, Hebert KE, Kamal M, et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res. 2004; 64:4506-4513. (Pubitemid 38856922)
23. Ruebel KH, Leontovich AA, Tanizaki Y, et al. Effects of TGFbeta1 on gene expression in the HP75 human pituitary tumor cell line identified by gene expression profiling. Endocrine. 2008; 33:62-76.
24. Zhang HY, Jin L, Stilling GA, et al. RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. Endocrine. 2009; 35:101-111.
25. Dunne J, Cullmann C, Ritter M, et al. siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8; 21)-positive cell lines and primary AML blasts. Oncogene. 2006; 25:6067-6078. (Pubitemid 44562405)
26. Tonks A, Pearn L, Musson M, et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia. 2007; 21:2495-2505. (Pubitemid 350148893)
27. Tonks A, Pearn L, Mills KI, et al. The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents. Leukemia. 2006; 20:1883-1885. (Pubitemid 44575000)
28. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92:2322-2333. (Pubitemid 28452973)
29. Chevallier N, Corcoran CM, Lennon C. ETO protein of t(8; 21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood. 2004; 103:1454-1463. (Pubitemid 38168662)
30. Liu S, Klisovic RB, Vukosavljevic T, et al. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther. 2007; 321:953-960. (Pubitemid 46762689)
31. Steffen B, Serve H, Berdel WE, et al. Specific protein redirection as a transcriptional therapy approach for t(8; 21) leukemia. Proc Natl Acad Sci U S A. 2003; 100:8448-8453. (Pubitemid 36842565)
32. Wang J, Saunthararajah Y, Redner RL, et al. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 1999; 59:2766-2769. (Pubitemid 29283104)